Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Long-Term Debt 2011-2026 | BPTS

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 1.83 M 5.4 M 6.38 M 661 K 820 K 273 K 537 K 330 K 305 K -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
6.38 M 273 K 1.84 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
167 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
410 K - 4.01 % $ 150 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
273 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
755 K - 1052.0 % $ 415 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
9.62 M - -0.23 % $ 916 M usaUSA
Adagene Adagene
ADAG
417 K $ 2.83 -2.75 % $ 159 M chinaChina
Biogen Biogen
BIIB
6.3 B $ 177.27 0.62 % $ 25.8 B usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
309 M $ 81.19 -0.98 % $ 1.57 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
2.42 B - - $ 40.3 B usaUSA
Amgen Amgen
AMGN
56.5 B $ 339.82 -0.91 % $ 182 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
4 M - - $ 1.01 B usaUSA
BioNTech SE BioNTech SE
BNTX
231 M $ 114.47 -1.97 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
4.76 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
278 K - -1.52 % $ 24.7 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
10.9 M $ 2.56 -0.78 % $ 16.1 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
59.9 K $ 3.23 -0.92 % $ 7.77 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
529 K - - $ 3.67 B usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
1.1 M $ 0.99 - $ 135 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
199 K $ 10.0 -1.43 % $ 658 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
210 K - 3.16 % $ 1.9 M usaUSA
AVROBIO AVROBIO
AVRO
188 K - 1083.1 % $ 745 M usaUSA
Cerus Corporation Cerus Corporation
CERS
11.7 M $ 2.3 -1.08 % $ 424 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
193 K - -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
1.88 M - -13.39 % $ 1.45 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
28.8 M $ 3.81 -4.51 % $ 116 M franceFrance
Brickell Biotech Brickell Biotech
BBI
146 K - -5.38 % $ 6.06 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
49 K - - $ 10.1 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
148 M $ 28.26 -3.52 % $ 2.33 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
175 M - - - russiaRussia
Athira Pharma Athira Pharma
ATHA
803 K - - $ 269 M usaUSA
Atreca Atreca
BCEL
60.3 M - -11.76 % $ 5.79 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
104 M $ 68.89 -0.33 % $ 9.21 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
2.79 M $ 24.53 -0.2 % $ 2.91 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
813 K $ 1.68 3.75 % $ 80.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
31 K - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
13.2 M - -10.17 % $ 12.2 K usaUSA
Akouos Akouos
AKUS
28.3 M - 0.23 % $ 488 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
25.7 M - -9.72 % $ 5.89 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
19.9 M - -15.15 % $ 60.3 M britainBritain
Berkeley Lights Berkeley Lights
BLI
22.7 M - -7.31 % $ 87 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
2.16 B $ 13.77 -2.45 % $ 4.25 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
2.63 M - 1.93 % $ 17.4 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
203 K - -74.18 % $ 955 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
25.4 M - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
146 K - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
3.38 M - - $ 2.17 B usaUSA